Reports
Sale
Diabetic Macular Edema Market Size, Share, Trends, Analysis: By Disease Type: Focal Diabetic Macular Edema (DME), Diffuse Diabetic Macular Edema (DME); By Treatment Type: Oral Iron Therapy, Parenteral Iron Therapy, Others; By Diagnosis; By Route of Administration; By Distribution Channel; By End User; Supplier Landscape; 2024-2032
Diabetic Macular Edema Market Outlook
The diabetic macular edema market size was valued at USD 6.7 billion in 2023, driven by the increasing incidence of diabetes cases within the 8 major markets. The market size is anticipated to grow at a CAGR of 5.1% during the forecast period of 2024-2032 to achieve a value of USD 10.4 billion by 2032.
Diabetic Macular Edema Market Overview
Diabetic retinopathy occurs in people with diabetes where the tiny blood vessels located at the back inner wall of the eye, known as the retina, get damaged or blocked by too much blood sugar. This can result in the formation of microaneurysms, which are tiny bulges in the blood vessels that leak fluid into the retina. The swollen fluid can cause vision problems or blindness in a part of the retina known as the macula, which is referred to as diabetic macular edema.
The market is driven by the rising prevalence of diabetes and diabetic macular edema. The prevalence rate of diabetic macular edema (DME) in type 2 diabetes patients is recorded to be higher than in type 1 diabetes patients. It is estimated that neovascular age-related macular degeneration (AMD) affects more than 200 million people worldwide. The increase in the number of research and development activities providing beneficial opportunities for treatment are driving the diabetic macular edema market growth. The rising approvals and launches of new drugs, along with rising investment in the development of advanced technologies is also expected to contribute to the market growth during the forecast period.
Technological Advancements to Develop Effective Solutions
The market growth is expected to be driven by several factors such as increased advancements in diagnostics technology and therapeutics for diabetic macular edema. For instance, in July 2023 researchers at the University of Waterloo’s School of Pharmacy developed a novel synthetic protein to treat macular degeneration and other incurable eye diseases that lead to blindness in millions of people. It is the first drug of its kind and is currently in human trials. Continuous efforts like these, focused at developing a cure for untreatable conditions are likely to increase the diabetic macular edema market share in the forecast period.
FDA Approvals to Aid the Market Growth
The market growth is propelled by rising FDA approvals to potent and cost-effective solutions to the patients. For instance, in August 2023, the United States FDA approved Regeneron’s EYLEA HD (aflibercept) Injection 8 mg for treating diabetic macular edema and other eye conditions. The approval was based on the results of 48-week PULSAR and PHOTON trials, wherein the potential candidate helped in significant vision gains in patients. This FDA approval will contribute to the widespread distribution and consumption of the pharmaceutical resulting in increased diabetic macular edema market value in the forecast period.
Diabetic Macular Edema Market Segmentations
Market Breakup by Disease Type
- Focal Diabetic Macular Edema (DME)
- Diffuse Diabetic Macular Edema (DME)
Market Breakup by Treatment Type
- Oral Iron Therapy
- Parenteral Iron Therapy
- Red Blood Cell Transfusion
Market Breakup by Diagnosis
- Hospitals Fluorescein Angiography
- Fundus Imaging
- Optical Coherence Tomography (OCT)
- Others
Market Breakup by Route of Administration
- Intravitreal Injections
- Intravitreal Implants
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by End User
- Hospitals
- Clinics
- Home Healthcare
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Diabetic Macular Edema Market Regional Analysis
Geographically, the United States is expected to lead throughout the forecast period, owing to the presence of a robust healthcare system and major market players. The continuous research activities in the region also contribute to the market growth. There has been significant emphasis on leveraging gene therapy to allow access to improved solutions. In November 2023, scientists deployed gene therapy ABBV-RGX-314 to allow controlled release of dexamethasone in patients with diabetic macular edema and retinal vein occlusion. Developed by collaborative efforts of RegenXBio and AbbVie, ABBV-RGX-314 is a monoclonal antibody fragment, administered through an injection. When tested in a cohort of 100 patients with DME, it reduced vision threatening events by 89% and prevented disease progression as well. Hence, it can be used as a potential treatment in the future.
Europe, with its robust healthcare infrastructure and significant portion of geriatric population has high diabetic macular edema market demand. Consequently, the existence of prominent academic and research institutions aids market size, with continuous developments and activities to develop effective solutions for the patients in the region.
Diabetic Macular Edema Market: Competitor Landscape
In May 2023, Oculis, a global pharmaceutical company prioritising eye care, revealed that their latest topical eye drop OCS-01, displayed positive results from stage 1 of phase 3 DIAMOND trial . The treatment provides an edge over current treatment alternatives of the disease, which mostly involve ocular implants or injections. It utilises Oculis' Optireach technology to deliver the effective medication to the retina. The rising prevalence for minimally invasive treatment alternatives has led to the development of relevant initiatives by industry leaders.
The key features of the diabetic macular edema market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- LEO Pharma
- Amneal Pharmaceuticals
- AstraZeneca
- Johnson & Johnson Private Limited
- Bausch Health Companies Inc.
- Eli Lilly and Company
- AbbVie Inc.
- Abbott
- F. Hoffmann-La Roche Ltd.
- Mylan N.V.
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Treatment Type |
|
| Breakup by Diagnosis |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Diabetic Macular Edema Market Overview – 8 Major Markets
3.1 Diabetic Macular Edema Market Historical Value (2017-2023)
3.2 Diabetic Macular Edema Market Forecast Value (2024-2032)
4 Diabetic Macular Edema Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Diabetic Macular Edema Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Diabetic Macular Edema Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Diabetic Macular Edema Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Diabetic Macular Edema Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Diabetic Macular Edema Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Diabetic Macular Edema Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Diabetic Macular Edema Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Diabetic Macular Edema Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Diabetic Macular Edema Epidemiology Scenario and Forecast (2017-2032)
6.5 India Diabetic Macular Edema Epidemiology Scenario and Forecast (2017-2032)
7 Diabetic Macular Edema Market Landscape – 8 Major Markets
7.1 Diabetic Macular Edema: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Diabetic Macular Edema: Product Landscape
7.2.1 Analysis by Treatment
7.2.2 Analysis by Product Type
8 Diabetic Macular Edema Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Diabetic Macular Edema Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.2.1 Strengths
10.2.2 Weaknesses
10.2.3 Opportunities
10.2.4 Threats
10.3 Porter’s Five Forces Model
10.3.1 Bargaining Power of Suppliers
10.3.2 Bargaining Power of Buyers
10.3.3 Threat of New Entrants
10.3.4 Threat of Substitutes
10.3.5 Degree of Rivalry
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Diabetic Macular Edema Market Segmentation (2017-2032) - 8 Major Markets
11.1 Diabetic Macular Edema Market (2017-2032) by Disease Type
11.1.1 Market Overview
11.1.2 Focal Diabetic Macular Edema (DME)
11.1.3 Diffuse Diabetic Macular Edema (DME)
11.2 Diabetic Macular Edema Market (2017-2032) by Treatment Type
11.2.1 Market Overview
11.2.2 Oral Iron Therapy
11.2.3 Parenteral Iron Therapy
11.2.4 Red Blood Cell Transfusion
11.3 Diabetic Macular Edema Market (2017-2032) by Diagnosis
11.3.1 Market Overview
11.3.2 Hospitals Fluorescein Angiography
11.3.3 Fundus Imaging
11.3.4 Optical Coherence Tomography (OCT)
11.3.5 Others
11.4 Diabetic Macular Edema Market (2017-2032) by Route of Administration
11.4.1 Market Overview
11.4.2 Intravitreal Injections
11.4.3 Intravitreal Implants
11.5 Diabetic Macular Edema Market (2017-2032) by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Retail Pharmacy
11.5.4 Online Pharmacy
11.5.5 Others
11.6 Diabetic Macular Edema Market (2017-2032) by End User
11.6.1 Market Overview
11.6.2 Hospitals
11.6.3 Clinics
11.6.4 Home Healthcare
11.6.5 Others
11.7 Diabetic Macular Edema Market (2017-2032) by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
11.7.5 India
12 United States Diabetic Macular Edema Market (2017-2032)
12.1 United States Diabetic Macular Edema Market Historical Value (2017-2023)
12.2 United States Diabetic Macular Edema Market Forecast Value (2024-2032)
12.3 United States Diabetic Macular Edema Market (2017-2032) by Disease Type
12.3.1 Market Overview
12.3.2 Focal Diabetic Macular Edema (DME)
12.3.3 Diffuse Diabetic Macular Edema (DME)
12.4 United States Diabetic Macular Edema Market (2017-2032) by Treatment Type
12.4.1 Market Overview
12.4.2 Oral Iron Therapy
12.4.3 Parenteral Iron Therapy
12.4.4 Red Blood Cell Transfusion
13 EU-4 and United Kingdom Diabetic Macular Edema Market (2017-2032)
13.1 EU-4 and United Kingdom Diabetic Macular Edema Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Diabetic Macular Edema Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Diabetic Macular Edema Market Overview
13.4 EU-4 and United Kingdom Diabetic Macular Edema Market (2017-2032) by Disease Type
13.4.1 Market Overview
13.4.2 Focal Diabetic Macular Edema (DME)
13.4.3 Diffuse Diabetic Macular Edema (DME)
13.5 EU-4 and United Kingdom Diabetic Macular Edema Market (2017-2032) by Treatment Type
13.5.1 Market Overview
13.5.2 Oral Iron Therapy
13.5.3 Parenteral Iron Therapy
13.5.4 Red Blood Cell Transfusion
14 Japan Diabetic Macular Edema Market
14.1 Japan Diabetic Macular Edema Market Historical Value (2017-2023)
14.2 Japan Diabetic Macular Edema Market Forecast Value (2024-2032)
14.3 Japan Diabetic Macular Edema Market (2017-2032) by Disease Type
14.3.1 Market Overview
14.3.2 Focal Diabetic Macular Edema (DME)
14.3.3 Diffuse Diabetic Macular Edema (DME)
14.4 Japan Diabetic Macular Edema Market (2017-2032) by Treatment Type
14.4.1 Market Overview
14.4.2 Oral Iron Therapy
14.4.3 Parenteral Iron Therapy
14.4.4 Red Blood Cell Transfusion
15 India Diabetic Macular Edema Market
15.1 India Diabetic Macular Edema Market (2017-2032) Historical Value (2017-2023)
15.2 India Diabetic Macular Edema Market (2017-2032) Forecast Value (2024-2032)
15.3 India Diabetic Macular Edema Market (2017-2032) by Disease Type
15.3.1 Market Overview
15.3.2 Focal Diabetic Macular Edema (DME)
15.3.3 Diffuse Diabetic Macular Edema (DME)
15.4 India Diabetic Macular Edema Market (2017-2032) by Treatment Type
15.4.1 Market Overview
15.4.2 Oral Iron Therapy
15.4.3 Parenteral Iron Therapy
15.4.4 Red Blood Cell Transfusion
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 LEO Pharma
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Amneal Pharmaceuticals
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 AstraZeneca
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Johnson & Johnson Private Limited
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Bausch Health Companies Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Eli Lilly and Company
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 AbbVie Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Abbott
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 F. Hoffmann-La Roche Ltd.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Mylan N.V.
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
List not exhaustive
23 Diabetic Macular Edema Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 6.7 billion in 2023 driven by increasing incidence of diabetes across the 8 major markets.
The market is anticipated to grow at a CAGR of 5.1% during the forecast period of 2024-2032 and is likely to reach a market value of USD 10.4 billion by 2032.
The increasing research and development activities to discover a cure for condition, integration of technical advancements and prevalence for minimally invasive treatments are fuelling the market demand.
The surge in FDA approvals to facilitate improved solutions to the patients is a major market trend. In August 2023, FDA approved Regeneron’s EYLEA HD (aflibercept) Injection 8 mg for treating diabetic macular edema and related eye conditions. The approval was based on the results of 48-week PULSAR and PHOTON trials, wherein the drug candidate helped in significant vision gains in patients.
Based on disease type, the market is divided into focal diabetic macular edema and diffuse diabetic macular edema.
Hospitals fluorescein angiography, fundus imaging, and optical coherence tomography (OCT) among others are common diagnostic methods.
The route of administration can include intravitreal injections and implants.
The major regions of the market include the United States, EU-4, the United Kingdom, Japan and India.
Various types of treatments include oral iron therapy, parenteral iron therapy, and red blood cell transfusion.
Major distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others.
End users in the market are hospitals, clinics, and home healthcare, among others.
Key players involved in the market are LEO Pharma, Amneal Pharmaceuticals, AstraZeneca, Johnson & Johnson Private Limited, Bausch Health Companies Inc., Eli Lilly and Company, AbbVie Inc., F. Hoffmann-La Roche Ltd., Mylan N.V., and Abbott.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER